Drug Trial Radar · NCT06666855
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
345
Actual
Start
Nov 28, 2024
Primary completion
Aug 31, 2026
Study completion Aug 31, 2026
Sponsor
- Lead sponsor
- Santen Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III Study that includes a single arm, open-label, multi-dose PK study cohort and a randomized, evaluator-masked, active drug-control multicenter study. Subjects diagnosed with POAG (Primary Open Angle Glaucoma) or OHT (Ocular Hypertension) who meet eligibility criteria will washout of their current IOP lowering medication(s), if any. The study will investigate plasma pharmacokinetics of multi-dose 0.002% DE-117B eye drops (1 drop at a time administered once daily for 7 days) in Chinese subjects with primary open angle glaucoma or ocular hypertension. It will investigate the safety of multi-dose 0.002% DE-117B eye drops (1 drop at a time administered once daily for 7 days) in Chinese subjects with primary open angle glaucoma or ocular hypertension. There will be a bridging cohort and extension follow-up phase
Conditions
- Open Angle Glaucoma
- Ocular Hypertension
Interventions
DE-117B Eye DropsDrug
Investigational Product: 0.002% DE-117B Eye Drops
LatanoprostDrug
Active Control: 0.005% Latanoprost Eye Drops
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intraocular Pressure (IOP) at Week 4Time frame: Week 4
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chao-Yang Hospital, Capital Medical University
Beijing, China
Beijing Hospital
Beijing, China
Beijing Tongren Hospital, Capital Medical University
Beijing, China
Peking University Third Hospital
Beijing, China
Zhongshan Ophthalmic Center
Guangzhou, China
Affiliated Hospital of Guizhou Medical University
Guiyang, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
Zhejiang Provincial People's Hospital
Hangzhou, China
Daqing People's Hospital
Heilongjiang, China
Jinan Second People's Hospital (Jinan eye hospital)
Jinan, China
The Second Hospital & Clinical Medicial Lanzhou University
Lanzhou, China
Luoyang third people's hospital
Luoyang, China
Qingdao Eye Hospital of Shandong First Medical University
Qingdao, China
Shanghai Eye Disease Prevention And Treatment Center/Shanghai Eye Hospital
Shanghai, China
Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong
Shantou, China
Shanxi eye hospital
Shanxi, China
Aier Eye Hospital (Liaoning)
Shenyang, China
The 4th People's Hospital of Shenyang
Shenyang, China
Shenzhen Eye Hospital
Shenzhen, China
Tianjin Eye Hospital
Tianjin, China
Wuhan Aier Eye Hospital
Wuhan, China
Wuhan Puren Hospital
Wuhan, China
Zhongnan Hospital Affiliated to Wuhan University
Wuhan, China
Wuxi Second People's Hospital
Wuxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.